SGLT2i in clinical cardiology
During this educational program, the effect of SGLT2 inhibition in patients with cardiorenal syndrome is disscussed in three lectures.
This course consists of the following lectures:
- The cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know? - Prof. Nikolaus Marx, MD - Aachen, Germany
- Heart & Kidney interactions: What are the challenges for prevention and protection? - Prof. Christoph Wanner, MD - Wurzburg, Germany
- Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials? - Prof. Faiez Zannad, MD - Nancy, France
After watching three videos on effects of SGLT2 inhibiton in patients with cardiorenal syndrome, the learner should be able to:
- Summarize the hemodynamic and metabolic effects of SGLT2 inhibition that are thought to underlie the observed CV benefits.
- Understand which potential mechanisms drive the early and mid- to long-term CV benefits of SGLT2 inhibiting treatment.
- Describe how the presence of renal failure affects prognosis of patients.
- Recall findings on kidney function in trials with SGLT2 inhibition and understand how these can be translated to treatment options.
- Recall the rationale of initial CV safety trials with novel glucose-lowering agents and what they showed regarding efficacy.
- Describe the first results obtained with an SGLT2 inhibitor in patients with HF with or without diabetes.
- Prof. Nikolaus Marx, Professor of Medicine / Cardiology, Head of Department of Internal Medicine I, Cardiology, Angiology, and Intensive Care Medicine, University Hospital Aachen, Germany
- Prof. Christoph Wanner, Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany
- Prof. Faiez Zannad is Professor of Therapeutics and Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy, France. He is also Director of the Clinical Investigation Centre (Inserm-CHU) in Nancy.
This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiorenal syndrome.
This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.
This is available as accredited online CME for members. Click the button below to enroll:Enroll